-
Your prediction
Hepion Pharmaceuticals Inc. Stock
Pros and Cons of Hepion Pharmaceuticals Inc. in the next few years
Pros
Cons
Performance of Hepion Pharmaceuticals Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Hepion Pharmaceuticals Inc. | - | - | - | - | - | - | - |
Evolus Inc | 2.940% | 16.667% | 21.739% | 64.706% | 54.696% | 51.351% | - |
Ardelyx Inc. | 5.770% | 6.941% | 7.836% | 67.751% | -1.903% | 364.754% | 79.034% |
Coherus Bioscien. | 4.560% | 8.696% | -18.879% | -71.053% | -59.293% | -90.553% | -93.737% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Initial Reflections on Hepion Pharma's Financials
Upon an immediate observation of the financial statements, several aspects of Hepion Pharma’s fiscal health become apparent. In particular, it’s noticeable that the Biotechnology & Medical Research company has undergone significant financial shifts over the last three years.
Intensive research and development expenditures, consistent net losses, and notable changes in their cash flow are all key features to consider when assessing the company’s financial position.